<DOC>
	<DOCNO>NCT00707512</DOCNO>
	<brief_summary>The primary objective study determine incidence pattern serious and/or clinically significant infection , malignancy , serious adverse event ( SAE ) participants Crohn 's Disease ( CD ) treat natalizumab . The secondary objective study study population evaluate disease severity time participant CD treat natalizumab base change Harvey-Bradshaw Index ( HBI ) .</brief_summary>
	<brief_title>CD INFORM : Investigating Natalizumab Through Further Observational Research Monitoring</brief_title>
	<detailed_description>This study originally conduct Elan Pharmaceuticals , Inc. ( Elan ) collaboration Biogen protocol write Elan . Biogen solely responsible study since April 2013 .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Natalizumab</mesh_term>
	<criteria>Key Subjects Crohn 's Disease ( CD ) eligible therapy accord US Tysabri label enrol Tysabri Outreach Unified Commitment Health ( TOUCH ) Prescribing Program . Key Exclusion criterion : Note : Other protocol define Inclusion/ Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>